Intravenous thrombolysis for pure pontine infarcts caused by cardiac myxoma: a case report and literature review

Int J Neurosci. 2020 Jun;130(6):635-641. doi: 10.1080/00207454.2019.1702537. Epub 2019 Dec 18.

Abstract

Purpose: Cardiac myxoma (CM) is a rare but important cause of ischemic stroke, and typically involves the middle cerebral artery and rarely affects the brainstem only. The safety and efficacy of intravenous thrombolysis (IVT) for CM-related acute cerebral embolism are not clear.Methods: We report a case of a 55-year-old woman who suffered a CM-related acute cerebral embolism presented with pure pontine infarcts and achieved a favorable prognosis by IVT with urokinase. We summarized the clinical data of this entity and performed a literature review of 21 previous reports of patients with CM-related acute cerebral embolism who were treated with IVT.Results: In combination with previous reports, we found that the majority of patients (81.8%) obtained improvements in symptoms after IVT, including 63.6% in remarkable clinical improvement. The total rate of IVT-induced intracerebral hemorrhage was 22.7% and all occurred within 36 h, including hemorrhagic infarction type 1 (4.5%) and parenchymal hematoma type 2 (18.2%). Most of the cases had relatively good outcomes and no case died due to IVT.Conclusion: Taken together, our findings support the use of IVT as an effective and safe tool for the ultra-early treatment of CM-related acute phase ischemic stroke.

Keywords: intravenous thrombolysis; Cardiac myxoma; echocardiography; pure pontine infarcts.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Administration, Intravenous
  • Brain Stem Infarctions / drug therapy*
  • Brain Stem Infarctions / etiology
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Heart Neoplasms / complications*
  • Humans
  • Middle Aged
  • Myxoma / complications*
  • Pons / blood supply
  • Pons / pathology
  • Stroke / drug therapy*
  • Stroke / etiology
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator